Epic Bio is building the world’s leading therapeutic platform based on the exciting new technology of epigenetic editing.
Lei Stanley Qi, Ph.D.
Lei Stanley Qi, Ph.D., is one of the leading CRISPR pioneers. He is a named co-inventor on the Nobel Prize-winning CRISPR patent held by the University of California, where he served as a doctoral candidate in the lab of Jennifer Doudna.
One of the most notable discoveries made by Dr. Qi was the first demonstration of the nuclease-deactivated Cas9 (dCas9) for sequence-targeted gene regulation in prokaryotic and eukaryotic cells. His lab has further developed a broad CRISPR toolbox of technologies for precise gene regulation, including epigenome editing (CRISPRa and CRISPRi), live cell DNA/RNA imaging (LiveFISH), 3D genome manipulation (CRISPR-GO), CRISPR antivirals for targeting RNA viruses (PAC-MAN), and the development of CasMINI, the smallest Cas protein created to work in human cells.
Dr. Qi holds a B.S. in math and physics from Tsinghua University, an M.A. in physics from the University of California, Berkeley, and a Ph.D. in bioengineering from the University of California Berkeley. He is an associate editor of The CRISPR Journal, a member of the scientific advisory board of the NIH Center for Genome Editing and Recording, and serves on the board of reviewing editors for Science.